Urbano
Anido Herranz
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (5)
2022
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
2020
-
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Therapeutic Advances in Medical Oncology, Vol. 12
2018
-
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
BMC Pharmacology and Toxicology, Vol. 19, Núm. 1
2017
-
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226
2016
-
The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma
Current Oncology Reports, Vol. 18, Núm. 11